Mary Van Beusekom | News Writer | CIDRAP NewsMay 25, 2020The data show the antiviral drug cut recovery time from 15 to 11 days.
Study: Remdesivir benefits some COVID-19 patients
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- Very few US adults getting new flu, COVID, RSV vaccines, even in nursing homes
- US respiratory virus activity remains low ahead of holiday season
- Antiviral COVID-19 drug molnupiravir tied to large drop in deaths in older patients
- Adults with migraines at higher risk of depression during pandemic, study shows